oncostatin M receptor
Dernière mise à jour 18 Aug 2020
Respecte les directives éditoriales
- TéléchargerTélécharger
- Partager
- Language
- Discussion
- Ask Patient
- Version audio
- Ajouter aux sources préférées sur Google
La OSMR gene provides instructions for making a protein called oncostatin M receptor beta subunit (OSMRβ). This protein is one piece (subunit) of both the oncostatin M (OSM) receptor type II and the interleukin-31 (IL-31) receptor. These receptors are embedded in the cell membrane of many types of cells throughout the body. Each attaches to a particular protein, fitting together like a lock and its key. This attachment triggers a series of chemical signals inside the cell that directs certain cell functions.
Sélections vidéo pour GènesBibliothèque vidéo
Normal function
La OSMR gene provides instructions for making a protein called oncostatin M receptor beta subunit (OSMRβ). This protein is one piece (subunit) of both the oncostatin M (OSM) receptor type II and the interleukin-31 (IL-31) receptor. These receptors are embedded in the cell membrane of many types of cells throughout the body. Each attaches to a particular protein, fitting together like a lock and its key. This attachment triggers a series of chemical signals inside the cell that directs certain cell functions.
OSM receptor type II interacts with a protein called oncostatin M (OSM). Signaling triggered by OSM was first recognized to block the growth of cancerous cells and appears to play a role in many other body processes, including the development of blood cells, the maturation of cells to become certain cell types, and an immune system response called inflammation. The signaling may also block the self-destruction (apoptosis) of cells.
The IL-31 receptor interacts with a protein called IL-31. Signaling triggered by IL-31 is involved in inflammation and stimulating itching (pruritus), although its role is not completely understood.
Conditions referring to this gene or chromosome
Other names
IL-31 receptor subunit beta
IL-31R subunit beta
IL-31R-beta
IL-31RB
interleukin-31 receptor subunit beta
oncostatin-M specific receptor beta subunit
OSMRB
PLCA1
Related patient information and medicines

Patient information leaflet
néphropathie à IgA
néphropathie à IgA is a condition in which a protein causes damage to the kidneys. The medicines used for blood pressure control with IgA nephropathy are angiotensin-converting enzyme (ACE) inhibitors ACE inhibitors or angiotensin receptor blockers (ARBs) - for example, losartan Losartan - an angiotensin receptor blocker. Even if you don't have high.

Patient information leaflet
Pontage aortocoronarien
C oronary artery bypass grafting (CABG) is a type of heart surgery to treat coronary artery disease. The standard surgery requires open heart surgery and stopping of the heart temporarily. Coronary artery bypass grafting, called CABG for short (pronounced 'cabbage'), is a heart operation. It is also called coronary artery bypass surgery. A CABG is.

Patient information leaflet
Cardiomyopathie dilatée
Cardiomyopathie dilatée is a condition where the heart muscle becomes stretched and thin. The heart becomes enlarged (dilates) and pumps blood less well. Symptoms vary according to severity and the treatment depends on the type of symptoms and whether any complications develop. Some forms of dilated cardiomyopathy run in families. A normal heart.

Patient information leaflet
Hypercholestérolémie familiale
Hypercholestérolémie familiale is inherited high cholesterol. The usual medicine to start with is a statin Statins and other lipid-lowering medicines. ...mmon statine used is called atorvastatinDr Krishna Vakharia , 13th September 2024 The National Institute for Health and Care Excellence (NICE) is recommending evinacumab alongside diet and other.

Patient information leaflet
Diabète et maladie
It is very important to know how to cope with illness if you have diabète or know or care for somebody with diabetes. Further information on managing diabetes pendant a period of illness est available sur le Diabète UK website (see Further Reading below for the link). On angiotensin-converting enzyme (ACE) inhibitors ACE inhibitors , angiotensin.

Patient information leaflet
Myasthénie grave
Myasthenia gravis (MG) is a condition where muscles become easily tired and weak. It is due to a problem with how the nerves stimulate the muscles to tighten (contract). The muscles around the eyes are commonly affected first. What causes myasthenia gravis. Myasthenia gravis is an autoimmune disease. This means that the immune system The immune.
Lectures complémentaires et références
- oncostatin M receptor; MedlinePlus, National Library of Medicine.
- Arita K, South AP, Hans-Filho G, Sakuma TH, Lai-Cheong J, Clements S, Odashiro M, Odashiro DN, Hans-Neto G, Hans NR, Holder MV, Bhogal BS, Hartshorne ST, Akiyama M, Shimizu H, McGrath JA. Oncostatin M receptor-beta mutations underlie familial primary localized cutaneous amyloidosis. Am J Hum Genet. 2008 Jan;82(1):73-80. doi: 10.1016/j.ajhg.2007.09.002.
- Chang YT, Wong CK, Chow KC, Tsai CH. Apoptosis in primary cutaneous amyloidosis. Br J Dermatol. 1999 Feb;140(2):210-5. doi: 10.1111/j.1365-2133.1999.02651.x.
- Hermanns HM. Oncostatin M and interleukin-31: Cytokines, receptors, signal transduction and physiology. Cytokine Growth Factor Rev. 2015 Oct;26(5):545-58. doi: 10.1016/j.cytogfr.2015.07.006. Epub 2015 Jul 3.
- Lin MW, Lee DD, Liu TT, Lin YF, Chen SY, Huang CC, Weng HY, Liu YF, Tanaka A, Arita K, Lai-Cheong J, Palisson F, Chang YT, Wong CK, Matsuura I, McGrath JA, Tsai SF. Novel IL31RA gene mutation and ancestral OSMR mutant allele in familial primary cutaneous amyloidosis. Eur J Hum Genet. 2010 Jan;18(1):26-32. doi: 10.1038/ejhg.2009.135.
- Wali A, Liu L, Takeichi T, Jelani M, Rahman OU, Heng YK, Thng S, Lee J, Akiyama M, McGrath JA, Betz RC. Familial primary localized cutaneous amyloidosis results from either dominant or recessive mutations in OSMR. Acta Derm Venereol. 2015 Nov;95(8):1005-7. doi: 10.2340/00015555-2104. No abstract available.
Partagez vos pensées ou expériences avec les autres dans notre communautés de patients.
Inscrivez-vous à la newsletter Patient
Votre dose hebdomadaire de conseils de santé clairs et fiables - rédigés pour vous aider à vous sentir informé, confiant et maître de la situation.
En vous abonnant, vous acceptez notre Politique de confidentialité. Vous pouvez vous désabonner à tout moment. Nous ne vendons jamais vos données.

